Form 4: STERIS plc VP & CAO Karen Burton Acquires Shares and Stock Options

Karen L. Burton, Vice President and Chief Accounting Officer of STERIS plc, has acquired 1,953 ordinary shares and 6,944 employee stock options, as reported in a recent SEC Form 4 filing.

Summary

• Karen L. Burton, VP & CAO of STERIS plc, acquired 1,953 ordinary shares on June 3, 2025, bringing her total beneficial ownership to 6,086 ordinary shares.
• Of the 6,086 ordinary shares beneficially owned, 3,522 are restricted and will vest on various dates between June 4, 2025, and June 5, 2028.
• Ms. Burton also acquired 6,944 employee stock options on June 3, 2025, with an exercise price of $267.66 per share and an expiration date of June 3, 2035.
• These stock options will become exercisable in four equal tranches of 1,736 options each, annually from June 3, 2026, to June 4, 2029.

Sentiment

Score: 7

Explanation: The acquisition of shares and options by a key executive is generally viewed positively as it aligns management's interests with shareholders and can indicate confidence in the company's future, although it is a routine compensation event.

Positives

• The acquisition of additional shares and stock options by a key executive like the VP & CAO can signal management's confidence in the company's future performance.
• The grants of shares and options at a $0 price for shares and $0 for options (implying a grant, not a purchase at market price) are typical compensation mechanisms that align executive incentives with shareholder value.

Negatives

• No inherent negatives are directly indicated by this Form 4 filing, as it primarily reports an executive's equity acquisition as part of compensation.

Future Outlook

The filing itself does not provide a future outlook for STERIS plc, but the grant of equity to a key executive suggests an expectation of continued performance and growth by the company's compensation committee.

Industry Context

This Form 4 filing is a routine disclosure of an insider transaction, common across all industries, reflecting executive compensation and equity incentive plans. It does not provide specific insights into broader industry trends for the healthcare or sterilization sectors in which STERIS plc operates.

Stakeholder Impact

• Shareholders: The transaction aligns the interests of a key executive with those of shareholders, potentially leading to better long-term performance.
• Employees: This reflects standard executive compensation practices, which can influence overall compensation philosophy within the company.

Next Steps

• Monitoring the vesting schedules for the restricted ordinary shares and employee stock options, which will occur on various dates between June 4, 2025, and June 4, 2029.

Key Dates

Recommendation

Keywords

STERIS plc, STE, SEC Form 4, Insider Transaction, Stock Options, Ordinary Shares, Executive Compensation, Karen L Burton, VP & CAO, Equity Acquisition